Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4145997 | 0.86 | GAA (0.42) | ACHEOPRD1ALDH1A1KMT2AHTT | |
| SCHEMBL3538646 | 0.85 | ACHE (0.34) | ACHEOPRD1ALDH1A1KMT2AHTT | |
| SCHEMBL4145688 | 0.85 | GAA (0.48) | ACHEOPRD1ALDH1A1KMT2AHTT | |
| SCHEMBL4146069 | 0.85 | GAA (0.44) | ACHEOPRD1ALDH1A1KMT2AHTT | |
| SCHEMBL10257602 | 0.84 | CHRNB2 (0.39) | ACHEOPRD1ALDH1A1KMT2AHTT | |
| SCHEMBL10257512 | 0.84 | CHRNB2 (0.39) | ACHEOPRD1ALDH1A1KMT2AHTT | |
| SCHEMBL4145570 | 0.83 | OPRD1 (0.33) | ACHEOPRD1ALDH1A1KMT2AHTT | |
| SCHEMBL4146772 | 0.83 | PARP1 (0.36) | ACHEOPRD1ALDH1A1LMNA | |
| SCHEMBL4148595 | 0.82 | OPRD1 (0.33) | ACHEOPRD1ALDH1A1KMT2AHTT | |
| SCHEMBL4152497 | 0.79 | HTR6 (0.37) | ACHEOPRD1ALDH1A1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-7425631-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-20050124654-A1 | Compounds and methods of use | AMGEN INC. | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124654-A1 | Compounds and methods of use | LTC4S, PTGES, LTB4R2 | ACHE 32/4885OPRD1 390/4885ALDH1A1 353/4885 |
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | LTC4S, PTGES, LTB4R2 | ACHE 32/4885OPRD1 390/4885ALDH1A1 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.